Mares of mixed breeding (379 to 594 kg) were injected intramuscularly once with Prostin F2 alpha | (PGF20t) in doses ranging between 0 and 10 mg between days 6 and 9 after ovulation. Prostaglandin F2a caused luteolysis as measured by reduction in intervals between injection and either return to estrus or ovulation and by reduction in interovulatory intervals for four of eight, seven of nine, eight of nine, four of eight, seven of nine and eight of eight mares treated with .25, 1, 2.5, 3, 5 or 10 mg PGF2a, respectively. Duration for both estrus and the estrous cycle subsequent to administration of Prostin F2 alpha was within the range accepted as normal indicating no carryover effects of treatment.
Sweating was not observed for mares treated with .25 mg PGF2a but was observed for mares treated with 1, 2.5, 3, 5 or 10 mg between 1/4 and 2 hr after injection. Most mares had ceased sweating within 1 hr after injection, but drying was not completed for up to 3 to 5 hr after injection. Rectal temperature was decreased significantly during the intervals 1/2 through 1, 1/2 through 4, 1/2 through 3", 1/2 through 5, or 1/4 through 5 hr after treatment of mares with 1, 2.5, 3, 5 or 10 mg PGF2a, respectively. Compared to appropriate controls, maximum temperature decrease of mares was on the order of .5 to .6 C for those treated with .25 or 1 mg, .9 to 1.2 C for those treated with 2.5, 3, or 5 mg, and 1.7 C for those treated with 10 mg PGF2a. Decreases in rectal temperature were associated with sweating and drying.
Neither heart nor respiration rates were Douglas and Ginther (1972) reported that doses of 1.25, 2.50, 5.00 and 10.00 mg PGF2a injected intramuscularly (IM) on day-6 of diestrus were equally effective in reducing the interovulatory interval of pony mares. Noden et al. (1974) either infused 10 mg PGF2a into the uterus or injected 15 mg PGF2a-Tham salt by weight subcutaneously (SC) once between days 7 to 9 post-ovulation of mares weighing 300 to 500 kilograms. Blood plasma progesterone concentration was reduced markedly within 12 hr after treatment, estrus began an average of 2.2 days after treatment, and ovulation was detected an average of 5.8 days after treatment. Data suggested that the duration of estrus detected following PGF2ct was longer than the duration of the control estrus, but the interval from ovulation to end of estrus was similar between the estrus prior to and the estrus subsequent to PGF2a treatment. The duration of the estrous cycles before and after the treatment estrous cycle were similar, indicating no carry-over effect of the PGF2a.
Purposes of this study were to compare effects of Prostin F2 alpha| doses ranging between 0 and 10 mg on luteolysis in the mare as measured by return to estrus and interovulatory intervals and on changes in rectal temperature, sweating, heart rate, and respiration rate.
MATERIALS AND METHODS
Thirty-six (36) mares (Study I) were as-JOURNAL OF ANIMAL SCIENCE, Vol. 42, No. 4 signed randomly in replicates to dose groups of O, 1, 3 or 5 mg Prostin F2 alpha| Mares were assigned to dose groups following detection of a normal estrus and ovulation.
Thirty-six (36) mares (Study II), 33 of which had been used in Study I, were assigned randomly in replicates to dose groups of 0, .25, 2.5 or 10 mg Prostin F2 alpha| Mares were assigned to dose groups following completion of an estrous cycle of normal duration.
General Management. These studies were executed during the interval June, 1974 through October, 1974 . Mares were of mixed breeding, weighed an average of 479 kg (range 379 to 594 kg), and were 3 to 21 years of age as estimated by evaluation of teeth. Each mare was teased daily with a Shetland pony stallion and one to three geldings if estrus was suspected but the mare would not respond to the Shetland pony. Mares were assumed to be in estrus if they stood firm with tail raised and exhibited contractions of the vulva either with or without concomitant squatting and urination while being teased. If there was a question as to whether or not a mare was in estrus, the stallion was allowed to mount the mare. Ovaries were palpated per rectum in order to measure foUicular development and to determine ovulation (follicle disappearance) each day during every estrous period from the first day of estrus through either the last day of estrus or until ovulation. Ovaries were palpated also on Monday, Wednesday and Friday during the interval between either last day of estrus or ovulation and first day of the next estrus.
Prostin F2 alpha| (5 mg PGF2a equivalents per milliliter) was diluted to the appropriate concentrations with sterile distilled water, and mares were injected intramuscularly once between days 6 to 9 after ovulation. Total volumes injected were 1.0 ml for doses of 0, .25, 1, 2.5 or 5 mg but 2.0 ml for 10 mg PGF2 a.
Heart rate (measured with a stethascope), respiration rate (number of exhalations per minute), rectal temperature, and degree of sweating were measured at 0, 1/4, 1/2, 3/4, 1, 1 1/2, 2, 3, 4, 5 and 6 hr post-injection. Sweating was quantitated as: 0 = no sweating; 1 = mild sweating about head and shoulders; 2 = moderate sweating over 1/2 to 3/4 of the body; 3 = beads of sweat over entire body and sweat dripping off body.
The terms pretreatment, post-treatment and subsequent estrus were used to designate the estrus prior to, and the first and second consecutive estrus after treatment, respectively. The treatment estrous cycle was measured from the first day of pretreatment estrus to the first day of post-treatment estrus. The post-treatment estrous cycle was measured from the first day of post-treatment estrus to the first day of subsequent estrus. Interovulatory intervals were the number of days between consecutive ovulations.
Analysis of variance was used to determine differences between treatment group means. If the analysis of variance indicated significant differences existed, the LSD was used to detect differences between means. Least square analysis for repeated measurements was used to analyze rectal temperature, heart rate, and respiration rate data (table 6). Treatment df were reduced to 1 for the main effect of hour and treatment x hour interaction in order to calculate conservative estimates of statistical significance for repeat measurements within mare (table 6) .
R ESU LTS

Luteolytic Effects of Prostin F2 alpha|
Due to a damaged rectum which prevented repeated rectal palpations, one of nine mares was eliminated from the 3 mg dose group after the pretreatment estrus. Differences were not significant for the intervals between pretreatment estrus of mares (Study I) and 1) the first day of estrus and ovulation (range of 2.2 to 4.0 days); 2) the first day of estrus and injection (range of 8.8 to 11.0 days); 3) the last day of estrus and injection (range of 5.0 to 7.2 days); 4) ovulation and injection (table 1); or 5) duration of estrus (range of 4.8 to 5.4 days). Intervals between pretreatment ovulation and end of estrus were .7, -.2, 1.6 and 1.9 days for mares treated with O, 1, 3 and 5 mg PGF2a, respectively. The interval of -.2 was different from both 1.6 and 1.9 (P<.05). This difference is assumed to be due to chance since no bias could be discerned concerning the random assignment of mares to the various dose groups.
Intervals between injection and ovulation were 15.8, 8.6, 11.5 and 8.9 days for mares injected with 0, 1, 3 and 5 nag PGF2a, respectively (table 1). Differences for intervals between control mares and those treated with 1 or 5 mg of PGF2a were significant, but only approached significance (P<.10) for the mares injected with 3 mg of PGF2a (tables 1, 3). (table 1) . Differences between interovulatory intervals were significant between control mares and those treated with 1 mg (P<.01), 3 mg (P<.05) or 5 mg (P<.01) of PGF2a (tables 1, 3) .
The interval between injection and the first day of estrus was 11.6, 5.8, 8.6 and 6.0 days for 0, 1, 3 and 5 mg PGF2a treated mares, respectively (table 1). Means for mares in both the 1 and 5 mg PGF2a dose groups were different from that of control mares (P<.05) but the difference between controls and mares treated with 3 mg approached (P<.10) significance (tables 1, 3). Percent mares detected in estrus within 10 days after injection was 0, 78, 50 and 78 for mares treated with 0, 1, 3 and 5 mg PGF2a, respectively (table 1). The 10-day interval was based on the minimum interval between injection and return to estrus for control mares in this band.
Characteristics measured for the post-treatment estrous cycles such as duration of estrus, interval between ovulation and end of estrus, interovulatory interval, and duration of subsequent estrus were similar between groups of mares (table 1) .
For Study II, nine mares were assigned to each dose group. However, one of nine mares in each of the 0, .25 and 10 mg dose groups were not detected in estrus following treatment 9 Each of the mares injected with .25 or 10 mg of PGFza were anestrus based on failure to detect follicles ~> 12 mm diameter in the ovaries 9
Differences were not significant statistically between treatment groups of mares for the intervals between pretreatment estrus (Study II) and 1) the first day of estrus and ovulation (range of 2.7 to 3.6 days); 2) the first day of estrus and injection (range of 9.6 to 11.0 days); 3) the last day of estrus and injection (range of 5.0 to 6.5 days); 4) ovulation and injection (table 2); 5) duration of estrus (range of 5.1 to 5.6 days); or 6) day of pretreatment ovulation and end of estrus (range of 1.2 to 1.6 days).
Intervals between injection and ovulation were 16.3, 12.4, 8.0 and 7.1 days for mares treated with 0, .25, 2.5 or 10 mg PGF2a, respectively (table 2). Differences in the intervals between both the control and .25 mg PGF20t treated mares were significant as compared to those of mares treated with 2.5 and 10 mg (tables 2, 3). lnterovulatory intervals for mares were 22.8, 20.1, 14.6 and 13.8 days for PGF20t dose groups O, .25, 2.5 and 10 rag, respectively (table 2). Differences were significant (P<.O1) for the interovulatory interval for both control mares and those treated with either 2.5 mg PGF2c~ as compared to mares treated with either 2.5 or 10 mg of PGF2a (tables 2, 3) .
The interval from injection to onset of estrus of mares was 13.5, 9.3, 4.4 and 3.8 days for O, .25, 2.5 and 10 mg PGF2a groups, respectively (table 2). The means for both the 0 and .25 mg PGF2~ dose groups of mares were significantly different (P<.O1) compared to the 2.5 and 10 mg dose groups of mares (tables 2, 3). Percent mares detected in estrus before 10 days after injection were 25, 50, 89 and 100 for treatments of O, .25, 2.5 or 10 mg of PGF20t respectively (table 2) .
Characteristics measured for the post-treatment estrous cycle of mares such as duration of estrus, interval between ovulation and end of estrus, interovulatory interval, and duration of subsequent estrus were similar for each treatment (table 2) .
Effect of Prostin F2 alpha| on Sweating, Rectal Temperature, Respiration Rate and
Heart Rate. Degree of sweating was none, mild or moderate to extensive for mares injected with .25, 1 or 2.5 mg or greater PGF2~, respectively (table 4) . In general, the degree of sweating for mares increased as dose of PGF2c~ was increased, but sweating had ceased by 3/4 to 3 hr after PGF2~ injection (table 4) .
In order to be declared as being reduced, an individual mean of interest had to be significantly different when compared to both the zero time mean within dose and the zero dose group mean within that time. Based on this criterion, rectal temperature was reduced significantly during the intervals 1/2 through 1, 1/2 through 4, 1/2 through 3, 1/2 through 5, or 1/4 through 5 hr after treatment of mares with 1, 2.5, 3, 5 or 10 nag PGF2~ respectively (table 5) . Maximum temperature reduction of mares was on the order of .5 to .6 C for treatments with .25 or 1 rag, .9 to 1.2 C for 2.5, 3 or 5 mg, and 1.7 C for 10 mg PGF2a when the data were compared to appropriate controls (table 5). Interval after injection at which maximum difference was detected between control and each dose group of mares was 1/2 hr for the .25 mg dose group, but 1 hr for the other dose groups (table 5) . These data reflect the basis for the treatment by hour interaction, i.e., rectal aSweating category: 0 = no sweating; 1 = mild sweating about head and shoulders; 2 = moderate sweating over 89 to 90 of the body; 3 = beads of sweat over entire body and sweat dripping off body. (table 6) .
Neither respiration rate (figures 1, 2) nor heart rate (figures 3, 4) was altered significantly (table 6) respectively. Over all dose groups, respiration rate was increased significantly at 1/4 and 1/2 hr. Heart rate was increased significantly at 1/4 hr in Study II. Over all dose groups, respiration rate of mares was decreased significantly during the intervals 2 through 6 hr for Study I, and heart rate was decreased significantly for 1 1/2, 2, 5 and 6 hr in Study I and 1 1/2 through 6 hr for Study II. This significant change over time was assumed to be due primarily to mares initially being nervous to being handled, but becoming accustomed to handling during the day.
Discussion
Doses of 1, 2.5, 3, 5 and 10 mg PGF~ were luteolytic as measured by interovulatory interval, interval between injection and either estrus or ovulation, or estrous cycle length. Based on limited numbers of mares assigned to each dose group, no significant differences were detected between those doses whereas the dose of .25 mg was significantly less effective. However, inspection of the data revealed a trend for the higher doses to result in both a higher percent of mares responding and shorter intervals between injection and return to estrus. Oxender et al. (1975) reported that subcutaneous doses of about 1.5 and 2.2 mg PGF2~ were luteolytic in 75% of eight mares. This 75% rate of effectiveness was similar to effectiveness of intramuscular doses of 2.5, 3 and 5 mg of PGF2c~ used in this study. However, doses of 3.75, 7.5 and 11.2 mg PGF2a have been reported (Noden et al., 1974; Oxender et al., 1975) . to be luteolytic in 100% of 17 mares. This 100% effectiveness was not attained except with the 10 mg intramuscular dose in this study. Douglas and Ginther (1972) reported that both interovulatory intervals and interval between injection (day 7 after ovulation) and ovulation were reduced significantly by doses of 1.25 mg or greater in the pony mare (110 to 279 kg). Also, IM or SC doses of 1.25 or .75 were more effective than a dose of .25 mg PGF2~ administered to pony mares (Douglas and Ginther, 1975) . Kenney et al. (1975) have reported a dose of 11.2 mg PGF2a to be about 93% effective for regressing CL of clincially anestrous mares that had a CL. Douglas and Ginther (1974) administered either .25 or 1.25 mg PGF2a intramuscular, intrauterine, or intraluteal and reported no significant difference in luteolytic dose between the routes of administration. In addition, no significant difference was found between intramuscular and subcutaneous administration of PGF2~ (Douglas and Ginther, 1975) . Data reported herein as well as published data suggest doses approaching 10 mg PGF2a to be luteolytic in about 100% of treated mares.
Data reported were similar between this study and previously reported studies for both interovulatory intervals and for interval between injection and either estrus or ovulation (Douglas and Ginther, 1972; Noden et al., 1974; Kenney et al., 1975; Oxender et al., 1975) . In addition, data reported demonstrated that both estrus and the estrous cycle were normal following administration of Prostin F2 alpha| To our knowledge, no one has systematically measured and reported changes in sweating, rectal temperature, heart rate, or respiration rate after administration of PGF2a.
The decrease in rectal temperature is postulated to be in response to sweating, i.e., rectal temperature decreased as mares sweated and returned to normal as mares ceased sweating and the sweat dried.
The general trend for both heart and respiration rates to increase suggested a dose effect, but the large variation between mares within dose groups precluded detection of statistically significant differences if they existed. An assumption was made that handling of mares resulted in heart rate and respiration rate changes that masked detection of PGF2a effects in these measurements.
These data demonstrate that the effects of luteolytic doses of PGF2a on changes in sweating, temperature as measured per rectum, heart rate, and respiration rate of mares were transitory. Studies are in progress which are designed to investigate cause and effect relationships between PGF2c~ and sweating in the mare.
